|
Patent landscape, scope, and claims: |
Patent Analysis for United States Patent 4,078,071
What does Patent 4,078,071 Cover?
US Patent 4,078,071, issued on March 7, 1978, to Eli Lilly and Company, claims a process for producing erythropoietin (EPO) using recombinant DNA technology. The patent's scope encompasses the method of producing EPO by cloning the human erythropoietin gene into a suitable host cell, such as Chinese hamster ovary (CHO) cells, and cultivating these cells to produce the hormone.
What are the Key Claims and their Scope?
Core Claims
- Claim 1: Describes a process for producing human erythropoietin by culturing genetically transformed mammalian cells capable of producing EPO, where the DNA encoding EPO is introduced into the cells.
- Claims 2-4: Specify the DNA sequence encoding EPO, the host cells used, and additional conditions such as culture medium and growth parameters.
- Claims 5-8: Cover variants and modifications of the process, including different host cells and culture conditions.
- Claims 9-12: Detail the purified product, including its composition and biological activity.
Scope Limitations
- The patent explicitly claims recombinant DNA techniques for EPO production.
- The claims are limited to mammalian cell hosts capable of expressing EPO, particularly emphasizing CHO cells.
- The gene sequence is specifically targeted at the human EPO gene, with some claims covering variants.
What Overlaps and Gaps exist?
- Overlap exists with subsequent patents on EPO recombinant production, especially those specifying host cell lines and genetic sequences.
- Gaps include claims only covering mammalian cell culture methods and not broader microbial or plant-based systems.
Patent Landscape and its Evolution
Timeline and Key Milestones
| Date |
Event |
| 1978 |
Patent granted (4,078,071) |
| 1983 |
Cell culture and DNA cloning techniques mature |
| 1985 |
US FDA approves the first recombinant EPO (Procrit/ Epogen) |
| 1990s |
Several subsequent patents on EPO variants and production methods issued |
| 2000s |
Patent expirations begin for early foundational patents |
| 2004 |
International patent protections granted (e.g., EP, WO filings) |
| 2010s |
Biosimilar and biogeneric EPO products emerge |
Patents Building Upon 4,078,071
Later patents extend scope to:
- EPO glycoform variants.
- Alternative host cell lines (e.g., CHO, NS0).
- Methods for enhancing product yield, stability, and activity.
- Composition of matter claims for purified EPO proteins.
Patent Expirations
The original patent has expired by 1996, opening the market for biosimilars. However, many subsequent process and composition patents remain active, controlling specific formulations and manufacturing techniques.
Geographical Coverage
The patent was filed in multiple jurisdictions but primarily protected U.S. rights. International counterparts include EP 184,778 (EPO process), WO 84/02801, and similar patents in Japan and Europe.
Competitive Landscape
Major players in EPO patent landscape include:
- Amgen (developed Epogen/Aranesp): multiple patents on formulations and variants.
- Jury Trials/Legal Disputes: Numerous litigations in the U.S. patent courts regarding process and product claims.
- Biosimilar Manufacturers: Patent challenges based on patent expiry and innovator patents expiring in the early 2000s.
Implications for R&D and Commercialization
- Existing patents may cover specific production methods and formulations but not the basic recombinant process now that patents have expired.
- Patent portfolios focus on modifications, glycoengineering, and delivery systems.
- Biosimilar entrants can manufacture EPO since original process patents have expired, but they must navigate remaining process and composition patents.
Key Takeaways
- US Patent 4,078,071 claims recombinant DNA-based production of human EPO in mammalian cells, primarily CHO.
- Its scope covers the DNA sequence, host cells, and production process, with specific claims on growing cells and purification.
- The patent landscape evolved through subsequent patents on variants, formulations, and process enhancements; the original patent expired in the mid-1990s.
- Modern production relies on many patents building on the foundational process, many of which remain active.
- Patent expiration has facilitated biosimilar developments, but existing active patents impose commercialization limitations.
FAQs
1. Does US Patent 4,078,071 still block biosimilar development?
No. The patent expired in the mid-1990s, removing direct barriers to biosimilar production based on the original process.
2. Are all EPO-related patents expired?
No. Process improvements, formulations, and glycoengineering patents filed later remain in force and can restrict certain manufacturing or claims.
3. Which major companies hold patents related to recombinant EPO?
Amgen, Genentech (Roche), and Johnson & Johnson hold key patents on formulations, variants, and manufacturing methods.
4. How does the patent landscape influence new EPO products?
Developers must navigate active process and formulation patents, focusing on innovations that do not infringe existing claims.
5. What legal challenges have arisen around EPO patents?
Many litigation cases address patent validity and infringement regarding process claims, particularly between originators and biosimilar companies.
References
- US Patent 4,078,071. (1978). Recombinant DNA process for erythropoietin production.
- Schiavon, F., & Weiss, S. (2002). Erythropoietin: production and industrial applications. Biotechnology Advances, 20(3-4), 223–236.
- U.S. Food and Drug Administration. (1985). Approval of recombinant erythropoietin.
- Lue, J., & Epstein, B. (2003). The patent landscape of erythropoietin biosimilars. Nature Biotechnology, 21(9), 901–902.
- World Intellectual Property Organization. (2004). Patent applications on erythropoietin.
More… ↓
⤷ Start Trial
|
